{"id":57940,"date":"2026-02-25T15:06:21","date_gmt":"2026-02-25T07:06:21","guid":{"rendered":"https:\/\/flcube.com\/?p=57940"},"modified":"2026-02-25T15:06:22","modified_gmt":"2026-02-25T07:06:22","slug":"united-labs-ubt251-achieves-19-7-weight-loss-in-phase-ii-triple-target-glp-1-gip-gcg-agonist-shows-blockbuster-potential","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57940","title":{"rendered":"United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II \u2013 Triple\u2011Target GLP\u20111\/GIP\/GCG Agonist Shows Blockbuster Potential"},"content":{"rendered":"\n

United Laboratories International Holdings Ltd (HKG:\u202f3933<\/a>)<\/strong> announced completion of a Phase II clinical trial<\/strong> for UBT251 Injection<\/strong>, its Category\u202f1 innovative triple\u2011target agonist<\/strong>, in Chinese patients with overweight\/obesity<\/strong>. The study demonstrated significant weight\u2011loss efficacy<\/strong> across all dose groups, with the maximum mean body weight reduction of -19.7% (-17.5\u202fkg)<\/strong> at Week\u202f24, positioning UBT251 as a potential competitor in the rapidly expanding metabolic disease market.<\/p>\n\n\n\n

Phase II Study Design & Results<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Study Design<\/strong><\/td>Randomized, double\u2011blind, parallel, placebo\u2011controlled<\/td><\/tr>
Enrollment<\/strong><\/td>205 patients<\/strong> with obesity or overweight + \u2265\u202f1 weight\u2011related comorbidity<\/td><\/tr>
Randomization<\/strong><\/td>1:1:1:1 (UBT251 2\u202fmg \/ 4\u202fmg \/ 6\u202fmg \/ placebo)<\/td><\/tr>
Administration<\/strong><\/td>Subcutaneous injection, once weekly \u00d7\u202f24 weeks<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Percentage change in body weight from baseline at Week\u202f24<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Efficacy Outcomes<\/h3>\n\n\n\n
Endpoint<\/th>UBT251 (All Doses)<\/th>Placebo<\/th>Treatment Effect<\/th><\/tr><\/thead>
Max Mean Weight Change<\/strong><\/td>-19.7% (-17.5\u202fkg)<\/strong><\/td>-2.0% (-1.6\u202fkg)<\/td>-17.7% vs. placebo<\/strong><\/td><\/tr>
Waist Circumference<\/strong><\/td>Significant improvement<\/td>Minimal change<\/td>Superior reduction<\/td><\/tr>
Blood Glucose<\/strong><\/td>Significant improvement<\/td>Minimal change<\/td>Metabolic benefit<\/td><\/tr>
Blood Pressure<\/strong><\/td>Significant improvement<\/td>Minimal change<\/td>Cardiovascular benefit<\/td><\/tr>
Blood Lipids<\/strong><\/td>Significant improvement<\/td>Minimal change<\/td>Lipid profile improvement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Safety Profile<\/h3>\n\n\n\n
Metric<\/th>Result<\/th><\/tr><\/thead>
Safety\/Tolerability<\/strong><\/td>Good across all dose groups<\/td><\/tr>
Discontinuations Due to AEs<\/strong><\/td>Zero patients<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile \u2013 UBT251<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Class<\/strong><\/td>Long\u2011acting triple\u2011target receptor agonist<\/td><\/tr>
Targets<\/strong><\/td>GLP\u20111<\/strong> + GIP<\/strong> + GCG<\/strong> (glucagon)<\/td><\/tr>
Mechanism<\/strong><\/td>Triple hormone pathway activation for weight loss, glycemic control, and metabolic improvement<\/td><\/tr>
Development Stage<\/strong><\/td>Phase II completed (obesity); Phase III pending<\/td><\/tr>
Other Indications<\/strong><\/td>Type\u202f2 diabetes, chronic kidney disease (CKD), MASH \u2013 approved for clinical trials in China and\/or US<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context \u2013 Novo Nordisk Partnership<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Deal Date<\/strong><\/td>March\u202f2025<\/td><\/tr>
Partner<\/strong><\/td>Novo Nordisk A\/S (NYSE:\u202fNVO)<\/td><\/tr>
Deal Value<\/strong><\/td>USD\u202f2\u202fbillion<\/strong><\/td><\/tr>
Licensed Territory<\/strong><\/td>Global excluding Greater China<\/strong> (China mainland, Hong Kong, Macau, Taiwan)<\/td><\/tr>
Novo Nordisk Rights<\/strong><\/td>Development, manufacturing, commercialization<\/td><\/tr>
United Labs Retained Rights<\/strong><\/td>Greater China development and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n